NCT06785519

CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis

A Clinical Study of the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 9 (estimated)
• Sponsor: He Huang · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Clinical Study of the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis.

Detailed description

In this study, 9 patients with relapsed refractory Lupus Nephritis were proposed to undergo CD19/BCMA CAR-T Cells therapy. Under the premise that its safety has been clarified in previous studies, further observation and evaluation of the effectiveness of CD19/BCMA CAR-T Cells therapy for relapsed refractory Lupus Nephritis; At the same time, on the basis of expanding the sample size, more safety data on CD19/BCMA CAR-T Cells treatment for relapsed refractory Lupus Nephritis were accumulated.

Conditions

• Lupus Nephritis

Interventions

Type	Name	Description
BIOLOGICAL	CD19/BCMA Lupus Nephritis Targeted CAR T-cells injection	Each subject receive CD19/BCMA Lupus Nephritis Targeted CAR T-cells by intravenous infusion

Timeline

• Start date: 2025-01-31
• Primary completion: 2027-10-31
• Completion: 2027-10-31
• First posted: 2025-01-21
• Last updated: 2025-01-21

Locations

1 site across 1 country: China